IMGN779, a Novel CD33-targeting antibody–drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML

Molecular Cancer Therapeutics

Volumn 17, Issue 6, 2018, Pages 1271-1279

  Kovtun, Yelena ^a   Noordhuis, Paul ^b   Whiteman, Kathleen R ^a   Watkins, Krystal ^a   Jones, Gregory E ^a   Harvey, Lauren ^a   Lai, Katharine C ^a   Portwood, Scott ^c   Adams, Sharlene ^a   Sloss, Callum M ^a   Schuurhuis, Gerrit Jan ^b   Ossenkoppele, Gert ^b   Wang, Eunice S ^c   Pinkas, Jan ^a  

^a IMMUNOGEN INC   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIBODY DRUG CONJUGATE; ANTILEUKEMIC AGENT; CASPASE 3; CYTOTOXIC AGENT; DGN 462; DNA; HISTONE H2AX; IMGN 779; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; CD33 ANTIGEN; CD33 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ACUTE MYELOID LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; DISEASE BURDEN; DNA ALKYLATION; DNA DAMAGE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR CELL INOCULATION; TUMOR XENOGRAFT; VALIDATION STUDY; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL CYCLE CHECKPOINT; CHEMICAL STRUCTURE; CHEMISTRY; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DNA DAMAGE; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, MYELOID, ACUTE; MICE; MOLECULAR STRUCTURE; NEOPLASTIC STEM CELLS; SIALIC ACID BINDING IG-LIKE LECTIN 3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85048093057     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-17-1077     Document Type: Article

References (33)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
2. Hackl H, Astanina K, Wieser R. Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. J Hematol Oncol 2017;10:51.
3. Saygin C, Carraway HE. Emerging therapies for acute myeloid leukemia. J Hematol Oncol 2017;10:93.
4. Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol 2015;94: 1127–38.
5. Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev 2017;31:43–62.
6. Al-Issa K, Nazha A. Molecular landscape in acute myeloid leukemia: where do we stand in 2016. Cancer Biol Med 2016;13:474–82.
7. Garfin PM, Feldman EJ. Antibody-based treatment of acute myeloid leukemia. Curr Hematol Malig Rep 2016;11:545–52.
8. Ku M, Chong G, Hawkes EA. Tumour cell surface antigen targeted therapies in B-cell lymphomas: beyond rituximab. Blood Rev 2017;31:23–35.
9. Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev 2014;28:143–53.
10. Jurcic JG. What happened to anti-CD33 therapy for acute myeloid leukemia? Curr Hematol Malig Rep 2012;7:65–73.
11. Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 2014; 53:3796–827.
12. Cowan AJ, Laszlo GS, Estey EH, Walter RB. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed) 2013;18:1311–34.
13. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121:4854–60.
14. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778–84.
15. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392–408.
16. Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 2012;30:1121–31.
17. Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, et al. A new class of antibody-drug conjugates with potent DNA alkylating activity. Mol Cancer Ther 2016;15:1870–8.
18. Broxterman HJ, Schuurhuis GJ, Lankelma J, Oberink JW, Eekman CA, Claessen AM, et al. Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain. Br J Cancer 1997;76:1029–34.
19. Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010;70:2528–37.
20. Kondo N, Takahashi A, Ono K, Ohnishi T. DNA damage induced by alkylating agents and repair pathways. J Nucleic Acids 2010;2010:543531.
21. Loganzo F, Sung M, Gerber HP. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther 2016;15:2825–34.
22. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94:1086–99.
23. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005;11:7764–72.
24. Tang R, Cohen S, Perrot JY, Faussat AM, Zuany-Amorim C, Marjanovic Z, et al. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of che-moresistance in cells from acute myeloid leukaemia patients. BMC Cancer 2009;9:199.
25. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 2000;14:1436–43.
26. Matsui H, Takeshita A, Naito K, Shinjo K, Shigeno K, Maekawa M, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 2002;16:813–9.
27. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003;102:1466–73.
28. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013;122:1455–63.
29. Gerratana B. Biosynthesis, synthesis, and biological activities of pyrrolo-benzodiazepines. Med Res Rev 2012;32:254–93.
30. Bixby DL, Stein AS, Fathi AT, Kovacsovics TJ, Levy MY, Erba HP, et al. Vadastuximab talirine monotherapy in older patients with treatment naive CD33-positive acute myeloid leukemia (AML) Blood 2016;128:590.
31. Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, et al. Vadastuximab talirine plus hypomethylating agents: a well-tolerated regimen with high remission rate in frontline older patients with acute myeloid leukemia (AML) Blood 2016;128:591.
32. Godwin CD, McDonald GB, Walter RB. Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood 2017;129:2330–2.
33. Applebaum FR, Bernstein ID. Gemtuzumab ozogamicin for actute myeloid leukemia. Blood 2017;130:2373–6.